Selecting which patients with hepatocellular carcinoma (HCC) are most likely to benefit from immunotherapy remains a central challenge in liver oncology. While immune checkpoint inhibitors have transformed outcomes for some patients, response rates remain variable, and robust predictive biomarkers have been lacking.
New data from an observational biomarker evaluation published this week in npj Precision Oncology provides fresh insight into potential immuno-oncologic biomarkers associated with response to checkpoint inhibitor–based therapy in HCC, using a large, real-world cohort drawn from multiple centres.
CLINICAL SUMMARY
What was examined
An analysis of tumour and clinical biomarkers associated with response to immune checkpoint inhibitor therapy in a large cohort of patients with advanced hepatocellular carcinoma.
Key findings
-
Tumour features reflecting immune activation were associated with higher response rates and improved survival on immunotherapy.
-
Immune-suppressed or immune-excluded tumour profiles were linked with poorer outcomes.
-
No single biomarker was sufficient to predict benefit, suggesting the need for multi-parameter strategies.
Clinical implications
-
Immunotherapy response in HCC appears biologically heterogeneous and not fully explained by clinical factors alone.
-
Biomarker-guided treatment selection may help refine sequencing and avoid ineffective therapy in the future.
-
Prospective validation will be needed before these markers can be incorporated into routine practice.
The investigators analysed tumour and clinical data from more than 1,300 patients with advanced HCC treated with immune checkpoint inhibitors, evaluating associations between molecular features and treatment outcomes. They aimed to identify biomarkers that could help refine patient selection and guide future precision approaches in liver cancer.
Several tumour characteristics were associated with improved outcomes on immunotherapy, including features reflecting a more inflamed tumour microenvironment. Markers linked to immune activation and antigen presentation were associated with higher response rates and longer survival, whereas tumours with immune-excluded or immune-suppressed profiles were less likely to benefit.
Importantly, the authors also observed heterogeneity within clinically similar patient groups, suggesting that conventional clinical factors alone may be insufficient to predict benefit from immunotherapy in HCC. Molecular profiling appeared to add additional discriminatory value beyond standard staging and liver function measures.
HER2 Uncovered: From Low to Ultralow – Get the Low Down with Ben Dessauvagie & Gelareh Farshid
The study further highlighted that no single biomarker was sufficient on its own, reinforcing the concept that composite or multi-parameter biomarker strategies may be required to meaningfully stratify patients.
Immune checkpoint inhibitors, particularly in combination regimens, are now embedded in first-line treatment for advanced HCC. However, many patients derive limited benefit while being exposed to potential toxicity and high cost. Better tools to predict response could help optimise sequencing, avoid futile treatment, and support more personalised care.
While the findings are exploratory and not yet ready for routine clinical use, they point toward a future in which immunotherapy selection in HCC may be guided by biological features of the tumour rather than solely by clinical characteristics. This is particularly relevant as molecular testing becomes more accessible and as biomarker-driven trials continue to expand in liver cancer.
For clinicians, the study underscores the need to view immunotherapy response in HCC as biologically heterogeneous and highlights the importance of ongoing research into predictive markers that could eventually inform routine decision-making.
Paper: Sharma, G., Baca, Y., Goel, S. et al. Evaluation of immuno-oncologic biomarkers and β-catenin expression in response to hepatocellular carcinomas to immunotherapy. npj Precis. Onc. (2026). https://doi.org/10.1038/s41698-026-01275-7
